Apolipoproteins C (ApoC)

A group of apolipoproteins that can readily exchange among the various classes of lipoproteins (HDL; VLDL; CHYLOMICRONS). After lipolysis of TRIGLYCERIDES on VLDL and chylomicrons, Apo-C proteins are normally transferred to HDL. The subtypes can modulate remnant binding to receptors, LECITHIN CHOLESTEROL ACYLTRANSFERASE, or LIPOPROTEIN LIPASE.

Also Known As:

Networked: 254 relevant articles (9 outcomes, 30 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Noma, M: 10 articles (02/2007 - 03/2002)
2.	Sékétéli, A: 10 articles (02/2007 - 03/2002)
3.	Amazigo, Uche V: 9 articles (07/2018 - 02/2007)
4.	Howlett, Geoffrey J: 8 articles (05/2019 - 03/2007)
5.	Noma, Mounkaila: 7 articles (06/2016 - 02/2012)
6.	Remaley, Alan T: 6 articles (02/2021 - 02/2015)
7.	Coffeng, Luc E: 6 articles (01/2021 - 01/2013)
8.	Stolk, Wilma A: 6 articles (01/2021 - 01/2013)
9.	Davignon, Jean: 6 articles (01/2017 - 11/2004)
10.	Wanji, Samuel: 6 articles (04/2015 - 08/2004)

Related Diseases

1.	Hypertriglyceridemia 07/01/2003 - "LPL activity remained in the range observed in C57/BL6J mice, and purified apoC-II transiently relieved FLS mice from hypertriglyceridemia. " 01/01/2020 - "Although apoC-II was first discovered nearly 50 years ago, there is renewed interest in it because of the recent efforts to develop new drugs for the treatment of hypertriglyceridemia (HTG). " 02/01/2016 - "ApoC-II deficiency in humans results in hypertriglyceridemia. " 02/01/2015 - "When added to serum from a patient with apoC-II deficiency, it restored normal levels of LPL-induced lipolysis and also enhanced lipolysis in serum from patients with type IV and V hypertriglyceridemia. " 07/01/2012 - "However, there is not enough current evidence to clarify whether increased apoC-II causes hypertriglyceridemia or is an epiphenomenon reflecting hypertriglyceridemia. "
2.	Onchocerciasis 12/01/2016 - "The study employed an African Programme for Onchocerciasis Control (APOC) onchocerciasis-related methodology. " 12/01/2010 - "The African Programme for Onchocerciasis Control (APOC) sponsored a baseline study in Nigeria between 1998 and 1999 on the prevalence and distribution of Onchocerciasis. " 01/01/2021 - "MDA has had a remarkable impact on the onchocerciasis burden in countries previously under the APOC mandate. " 01/01/2021 - "This enabled APOC to use Rapid Epidemiological Mapping of Onchocerciasis, which entailed identifying likely vector breeding sites near rivers, then sampling 50 adult males in nearby villages to determine the prevalence of nodules and delineate which villages required treatment. " 12/30/2020 - "Data from 19 countries that participated in the World Health Organization (WHO) sponsored African Programme for Onchocerciasis Control (APOC), from 1995 until 2015, were compared with thirty-five (Non-APOC), countries that were not included. "
3.	Hyperlipidemias (Hyperlipidemia) 11/01/1985 - "The tendency for decreased plasma apoC levels following alimentary lipemia confirms previous reports, and provides further data to support the concept that some apoC is cleared from plasma in association with TRL remnants. " 06/01/2006 - "Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL." 03/28/2000 - "Genetic deficiencies of apoC-II and overexpression of apoC-II in transgenic mice are both associated with severe hyperlipidemia, indicating a complex role for apoC-II in the regulation of blood lipid levels. " 01/01/1993 - "The variant may be altered in some other property, such as lipid binding, but since the distribution of apoC-IISF revealed no simple co-inheritance with lipid levels, it is unclear to what extent it plays a role in the observed hyperlipidemia. " 12/09/1981 - "The results suggest that as far as total levels are concerned, changes of apoC-II, apoC-III and the ratio of apoC-II/apoC-III appear to have no effect on the development of hyperlipidemia in th nephrotic syndrome."
4.	Insulin Resistance 06/01/2010 - "The serum levels of apoC-I in the patients with PCOS were statistically significantly elevated compared with those of controls, especially in women with insulin resistance. " 11/01/2012 - "WAT apoC-I secretion over 4 hours correlated with fasting total and non-high-density lipoprotein apoC-I but not with high-density lipoprotein apoC-I and was the primary predictor of 4-hour postprandial increases in TRL apoC-I. Correction for TRL apoC-I eliminated the association of WAT apoC-I with 6-hour area under the curve of plasma (13)C-triglyceride; correction for insulin sensitivity or inflammation did not. " 09/01/2014 - "Plasma apoC-I, apoC-II, apoC-III, and apoE are not associated with adiposity, insulin sensitivity, or inflammation in obese but healthy postmenopausal women. " 12/01/2009 - "In multiple regression models, these associations, excluding TG/cholesterol ratio of LDL, remained significant and independent of possible confounders including age, sex, body mass index, insulin resistance index (HOMA-IR), and adiponectin, whereas the associations of ANGPTL3 with the lipoprotein parameters were less significant when apoC-II/C-III ratio was included in the models. " 09/01/2010 - "In a cross-sectional observational study, IMT, skin AF, lipids and apolipoproteins, C-reactive protein (CRP), insulin resistance and paraoxonase-1 activity were measured in 59 non-smoking, non-obese subjects without diabetes mellitus and cardiovascular disease (32 women; 12 subjects with metabolic syndrome (MetS)). "
5.	Inflammation (Inflammations) 06/01/2018 - "Apolipoproteins C-II and C-III as nutritional markers unaffected by inflammation." 06/01/2018 - "These results indicate that ApoC-II and ApoC-III are appropriate nutritional biomarkers unaffected by inflammation." 11/01/2012 - "WAT apoC-I secretion over 4 hours correlated with fasting total and non-high-density lipoprotein apoC-I but not with high-density lipoprotein apoC-I and was the primary predictor of 4-hour postprandial increases in TRL apoC-I. Correction for TRL apoC-I eliminated the association of WAT apoC-I with 6-hour area under the curve of plasma (13)C-triglyceride; correction for insulin sensitivity or inflammation did not. " 09/01/2014 - "Plasma apoC-I, apoC-II, apoC-III, and apoE are not associated with adiposity, insulin sensitivity, or inflammation in obese but healthy postmenopausal women. " 09/01/2014 - "At baseline, there was no association between the plasma transferable apolipoproteins with any index of adiposity, insulin sensitivity, lipids, or inflammation, except for apoE with peripheral fat mass (r = 0.18, P < .05), and apoC-II and apoC-III with cholesterol (r = 0.23 and r = 0.20 respectively, P < .05). "

Related Drugs and Biologics

1.	Triglycerides (Triacylglycerol)
2.	Lipoprotein Lipase (Diacylglycerol Lipase)
3.	Ivermectin (Mectizan)
4.	Peptides (Polypeptides)
5.	Lipoproteins (Lipoprotein)
6.	Apolipoprotein C-III
7.	Apolipoprotein C-II (ApoC2)
8.	Cholesterol
9.	HDL Lipoproteins
10.	Apolipoproteins

Related Therapies and Procedures

1.	Cardiopulmonary Resuscitation (CPR)
2.	Resuscitation
3.	Therapeutics
4.	Radiotherapy
5.	Drug Therapy (Chemotherapy)